Needham & Company LLC Raises Pacira BioSciences (NASDAQ:PCRX) Price Target to $32.00

Pacira BioSciences (NASDAQ:PCRX) had its price target lifted by analysts at Needham & Company LLC from $30.00 to $32.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s target price points to a potential upside of 25.54% from the stock’s current price.

PCRX has been the topic of several other research reports. Barclays cut their price objective on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a report on Thursday, March 26th. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $30.75.

Pacira BioSciences Price Performance

Shares of PCRX opened at $25.49 on Friday. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. Pacira BioSciences has a 1 year low of $18.80 and a 1 year high of $27.64. The stock has a market cap of $1.00 billion, a P/E ratio of 169.93 and a beta of 0.19. The stock’s 50-day moving average price is $23.31 and its two-hundred day moving average price is $23.14.

Pacira BioSciences (NASDAQ:PCRX) last issued its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The company had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. During the same quarter last year, the business posted $0.91 EPS. Pacira BioSciences’s quarterly revenue was up 5.1% on a year-over-year basis. On average, equities analysts predict that Pacira BioSciences will post 1.85 earnings per share for the current year.

Insider Buying and Selling at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the sale, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Shawn Cross sold 12,941 shares of Pacira BioSciences stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total transaction of $325,595.56. Following the completion of the sale, the chief financial officer owned 105,341 shares in the company, valued at $2,650,379.56. The trade was a 10.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 32,261 shares of company stock worth $785,850. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Hsbc Holdings PLC raised its stake in shares of Pacira BioSciences by 8.2% during the 1st quarter. Hsbc Holdings PLC now owns 19,922 shares of the company’s stock worth $457,000 after purchasing an additional 1,506 shares in the last quarter. Greenwood Capital Associates LLC raised its stake in shares of Pacira BioSciences by 18.0% during the 1st quarter. Greenwood Capital Associates LLC now owns 22,795 shares of the company’s stock worth $515,000 after purchasing an additional 3,471 shares in the last quarter. Inspire Investing LLC raised its stake in shares of Pacira BioSciences by 25.7% during the 1st quarter. Inspire Investing LLC now owns 22,574 shares of the company’s stock worth $510,000 after purchasing an additional 4,616 shares in the last quarter. Foster & Motley Inc. raised its stake in shares of Pacira BioSciences by 38.8% during the 1st quarter. Foster & Motley Inc. now owns 57,000 shares of the company’s stock worth $1,288,000 after purchasing an additional 15,943 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in shares of Pacira BioSciences during the 1st quarter worth approximately $411,000. Institutional investors own 99.73% of the company’s stock.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Q1 results beat expectations — Pacira reported $0.60 EPS vs. $0.55 consensus and revenue of $177M vs. $171.8M consensus; revenue rose ~5% YoY and EXPAREL volumes grew ~7%, signaling continued commercial recovery. Read More.
• Positive Sentiment: Pipeline and clinical milestones are advancing — company completed enrollment in the Phase 3 shoulder osteoarthritis study for ZILRETTA (topline readout expected by year-end) and is progressing PCRX-201 Phase II work, which supports future growth optionality beyond branded injectables. Read More.
• Neutral Sentiment: FY‑2026 revenue guidance set to $745M–$770M (consensus ~ $761.5M) — guidance range brackets the street forecast but sits slightly below the consensus midpoint, leaving modest near‑term upside/ downside risk depending on execution. Read More.
• Negative Sentiment: Uncertainty on margins/valuation and lack of explicit EPS guidance increase short‑term investor caution — net margin remains compressed and the stock trades at a high P/E, which could amplify reactions to any execution slips or weaker guidance cadence. Read More.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.